Ideas

Interleukin-based therapy for diabetes: IL-22 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 26/January/2019, 11.26 pm
Interleukin-based therapy for diabetes: IL-22 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 26/January/2019, 11.26 pm 960 720 Dr Boomi's Genom-2-Discovery Center

 Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more

Ribonucleic acid-based therapy for Myocardial Infarction: LncRNA GAS5 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 26/January/2019, 12.08 am
Ribonucleic acid-based therapy for Myocardial Infarction: LncRNA GAS5 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 26/January/2019, 12.08 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA SNHG1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 25/January/2019, 11.55 pm
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA SNHG1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 25/January/2019, 11.55 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more

Natural product-based combinatorial therapy for inflammation and arthritis: A pharmaceutical mixture encompassing Fisetin & Quercetin increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 25/January/2019, 11.48 pm
Natural product-based combinatorial therapy for inflammation and arthritis: A pharmaceutical mixture encompassing Fisetin & Quercetin increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 25/January/2019, 11.48 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that “Resolution of inflammation by…

read more

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA NRF2-AS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 24/January/2019, 8.17 pm
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA NRF2-AS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 24/January/2019, 8.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more

Ribonucleic acid-based therapy for Myocardial Infarction: LncRNA THRIL  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 24/January/2019, 8.07 pm
Ribonucleic acid-based therapy for Myocardial Infarction: LncRNA THRIL  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 24/January/2019, 8.07 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say:  Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Ribonucleic acid-based therapy for Myocardial Infarction: LncRNA THRIL  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte…

read more
Start Typing